Roivant Sciences Ltd. (NASDAQ:ROIV) Q1 2023 Earnings Conference Call August 14, 2023 8:00 AM ET

Company Participants

Stephanie Lee - Vice President, Special Projects

Matthew Gline - Chief Executive Officer

Mayukh Sukhatme - President and Chief Investment Officer

Conference Call Participants

Brian Chen - JPMorgan

David Risinger - Leerink

Robyn Karnauskas - Truist Securities

Louise Chen - Cantor

Dennis Ding - Jefferies

Yaron Werber - Cowen

Douglas Tsao - H.C. Wainwright

Operator

Good morning, ladies and gentlemen, thank you for standing by. Welcome to the Roivant’s First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please note that today’s conference is being recorded.

I will now hand the conference over to your speaker host today, Stephanie Lee. Please go ahead.

Stephanie Lee

Good morning, and thanks for joining today’s call to review Roivant’s financial results for the company’s first quarter ended June 30, 2023. I’m Stephanie Lee with Roivant.

Presenting today, we have Matt Gline, CEO of Roivant and Mayukh Sukhatme, President and Chief Investment Officer for Roivant. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investors.roivant.com. We’ll also be providing the current slide numbers as we present to help you follow a along.

I’d like to remind you that we’ll be making certain forward-looking statements during today’s presentation. We strongly encourage you to review the information that we filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties.

And with that, I’ll turn it over to Matt.

Matthew Gline

Thank you, Stephanie, and thank you, everybody, for joining this morning and for listening. It’s only been a short – actually 6 weeks since our last call, as our last call was for the K. So comparatively a little bit tougher updates, but an exciting – certainly an exciting quarter ended June 30 and a lot to talk about today.

I’m going to give just a brief – a brief sort of update on the state of the business as well as an update on the quarter and VTAMA sales. And then actually, what we’re going to spend the bulk of time on today is we’ve been getting more questions about brepocitinib and we’ve actually got some new data there in Crohn’s disease. So we’re going to share that and talk through again a reminder of sort of how we’re thinking about that program as we approach the lupus data in the back half of the year and more beyond.